At a Glance
- Companies: AAX Biotech; Vascurie
- Location: Undisclosed (likely US/Europe biotech hubs)
- Headline figure: Undisclosed; up to 100 antibodies characterized in parallel
- Focus area: Neuro‑oncology; Seqitope epitope‑mapping and robotics platform
- Next steps: High‑throughput antibody characterisation for Vascurie programs
What happened?
AAX Biotech and Vascurie have announced a neuro‑oncology discovery collaboration leveraging AAX’s Seqitope epitope‑mapping and robotics platform to characterize up to 100 antibodies in parallel for Vascurie’s therapeutic programs.
Why does it matter?
Neuro‑oncology remains underserved despite advances in immunotherapy, with antibody discovery bottlenecked by slow epitope characterization limiting precision targeting of brain tumours. AAX’s high‑throughput platform accelerates functional validation, enabling Vascurie to prioritise candidates with optimal binding profiles for glioblastoma and other CNS malignancies.
Who’s behind it?
AAX Biotech develops the Seqitope platform combining robotics, sequencing and computational mapping for parallel epitope analysis across hundreds of antibodies. Vascurie focuses on neuro‑oncology therapeutics requiring advanced antibody optimisation for brain penetration and tumour specificity.
How was it achieved?
AAX provides robotics‑enabled epitope mapping services, delivering comprehensive binding profiles, affinity data and functional insights for up to 100 Vascurie antibodies simultaneously. The platform’s parallel processing reduces timelines from months to weeks.
What’s next?
Vascurie will use Seqitope data to nominate lead candidates for preclinical development, potentially advancing optimised antibodies into CNS models. Success could expand the collaboration to additional neuro‑oncology targets.
What are people saying?
AAX highlighted Seqitope’s ability to “unlock antibody potential at unprecedented scale.” Vascurie noted the partnership accelerates their path to differentiated neuro‑oncology therapies.